June 5th 2025
Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Bystander Activation of T Cells May Be Cause of Persistent Arthritis in Lyme Disease
February 9th 2018A small portion of individuals with Lyme disease continue to have symptoms of arthritis long after treatment. Now, scientists think they have a better understanding of the cause of that lingering reaction.
Read More
HHS Tick-Borne Disease Working Group Begins Efforts Despite Controversies: Public Health Watch
December 13th 2017The US Department of Health and Human Services Tick-Borne Disease Working Group held its first public meetings in Washington, DC, this week and it has already generated plenty of eye-grabbing headlines.
Read More
SIGA Technologies, Inc Submits NDA for First-Ever Oral Smallpox Treatment
December 12th 2017Although deemed eradicated throughout the world in 1980 thanks to a protective vaccine, research on smallpox continues to this day given the potential for the highly contagious virus to be used in biological warfare.
Read More